GHP Q4 2021

6 GHP / Q4 2021 , Apr21057 Based in Zurich, Switzerland, Smart Blood Analytics Swiss SA is a pioneering R&D company that has championed the use of advancedmachine learning algorithms in AI models that canmore accurately and efficiently predict diseases andmedical conditions based on individual’s blood test results solely. The company released on the market twomedical devices. First is SBAS Software which is intended for physician, andmySmartBlood, a mobile application intended for symptomatic end-users. We find out more following the company’s recent award forMost InnovativeMachine Learning Blood Analytics Tool, 2021. Blood test interpretation using AI For effective detection, diagnosis and treatment of more than 70 % of diseases, blood tests results are vital. Thanks to timely and accurate blood tests results, professionals and leading authorities of the global medical and healthcare sectors can ensure diagnoses and early intervention for patients that will facilitate better quality of care further down the line and efficiency in managing downstream costs. However, the interpretation of blood test results can become unnecessarily complicated when multiple parameter values are out of the normal range – or indeed, even when all of those values are within the normal range. Fortunately, Smart Blood Analytics Swiss SA (SBAS) offers a solution. The Zurich-based company was founded in 2016 by Dr. Marko Notar, who still sits at the helm of SBAS and its work at the forefront of the world’s medical research sector. “The current health care system is increasingly dependent on reliable blood test results, the true power of which is frequently underestimated,” states Dr. Notar on the SBAS website. “They carry way more information than we ever thought possible. Blood test results represent information and not the knowledge itself. Together they form the true power of Artificial Intelligence, which is efficiently combined in our products.” A small but flexible and highly specialised organisation with globally renowned expertise in the interpretation of blood test results, SBAS is defined by its innovative approach to its science. This approach primarily centres on the belief in the power of artificial intelligence and its benefits to the future of medical research. Using advanced machine learning algorithms, SBAS is able to provide a broad portfolio of AI models that can accurately and efficiently predict the most probable diagnoses based solely on an individual’s blood test results from the field on internal medicine and neurology. As a result, SBAS is able to offer probable diagnoses and expanding differential diagnosis leading to more effective treatment and better overall outcomes. This process has been perfected in the firm’s first flagship product, the SBAS Software. A cloud- based software service that is accessible through either an API or web-application, SBAS Software employs a two-step process. The first step is to gather its patients’ blood test results that include complete blood count with differential and common parameters from biochemistry, haemostatic, enzyme, lipid, protein & amino acids, vitamins and hormone panels. This usually provides sufficient data for the SBAS Software models to predict the most probable disease, confirm a human- made diagnosis, or expand the differential diagnosis. These ground-breaking models have been built on SBAS’s signature machine-learning algorithms to analyse hundreds of groups of medical conditions and diseases across the field of internal medicine, ranging from rheumatology to cardiology, toxicology, haematology to endocrinology, pulmonology and nephrology to gastroenterology and field of neurology. The SBAS Software is also able to recognise disease-related blood laboratory patterns that go beyond existing medical knowledge. As a result, SBAS’s solutions offer higher diagnostic accuracy compared to traditional quantitative interpretations based only on reference ranges. SBAS is then able to deliver a comprehensive report complete with a list of ten of the most likely diseases with the corresponding ranking factors and parameter evidence and an intuitive multilevel pie chart – a valuable asset in increasing the efficiency and improving the accuracy of a doctor’s diagnostics. Consequently, SBAS’s pioneering solution is recognised internationally for its benefits in improving the diagnostic process as it enables doctors to make more accurate and more efficient decisions, resulting in better outcomes for patients and reduced costs for healthcare systems. As a result, SBAS’s team of professionals within the fields of medicine, machine learning, laboratory biomedicine and chemistry have since been called upon to take their solution even further.